Trial Profile
Efficacy and safety of a single dose of 14.8 MBq/kg (0.4 mCi/kg)90Y-ibritumomab tiuxetan ("Zevalin") in elderly patients with diffuse large B-cell lymphoma and FDG-PET positive partial remission following first-line R-CHOP therapy. A Phase II clinical trial (HOVON 77).
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 29 Apr 2014
Price :
$35
*
At a glance
- Drugs Ibritumomab tiuxetan (Primary) ; Rituximab
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- Acronyms HOVON-77-NHL
- 11 Nov 2009 New trial record